A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients
Sponsor: Pfizer
A PHASE3 clinical study on HIV Infections and Mycobacterium Avium-Intracellulare Infection, this trial is completed. The trial is conducted by Pfizer and has accumulated 6 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Dallas, United States
- • Houston, United States
- • Los Angeles, United States
- • Orange, United States
- • Philadelphia, United States
- • San Diego, United States
- • San Jose, United States
- • Torrance, United States
- • Washington D.C., United States
- • Worcester, United States